23 Aug Checkpoint Inhibitors’ Adverse Events Linked to Tumor Mutational Burden
MedicalResearch.com Interview with:
Prof. Flatz
Prof. Dr. Lukas Flatz MD
Institute of Immunobiology
Kantonsspital St Gallen, St Gallen
Switzerland
MedicalResearch.com: What is the background for this study?
Response: Toxicity is an important limiting factor of treatment with checkpoint inhibitors. We aimed in investigating the relationship between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden by comparing large scale surveillance data of irAEs with the median tumor mutational burden across multiple cancer types.
MedicalResearch.com: What should readers take away from your report?
Response: Our study shows that a high tumor mutational burden is associated with a higher risk to develop toxicity during treatment. Our data suggest that a patient suffering from a tumor with a high tumor mutational burden is regularly followed-up for the development of toxicity during the treatment. The tumor mutational burden may help the treating doctor to estimate the risk for developing toxicity during treatment.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: While our publication shows an association between tumor mutational burden and immune-related adverse event we do not yet understand the exact underlying mechanism. Our laboratory team (see www.flatzlab.com) is currently using a prospective cohort to decipher the underlying mechanisms.
See the disclosures in the publication.
Citation:
JOIN OUR EMAIL LIST
[mailpoet_form id="5"]We respect your privacy and will never share your details.
Last Modified: [last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on August 23, 2019 by Marie Benz MD FAAD